Resources from the same session
576MO - Health-related quality of life (HRQoL), pain and safety outcomes in the phase III VISION study of <sup>177</sup>Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
Presenter: Karim Fizazi
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA26 - Darolutamide maintenance in metastatic castration resistant prostate cancer (mCRPC) previously treated with novel hormonal agents (NHA) and non-progressive disease after subsequent treatment with a taxane: A randomized double-blind placebo-controlled phase II trial (SAKK 08/16)
Presenter: Richard Cathomas
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
578MO - Phase Ib/II study of sabizabulin (VERU-111), an androgen receptor transport disruptor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent (ARTA)
Presenter: Mark Markowski
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast
579MO - CheckMate 9KD cohort A2 final analysis: Nivolumab (NIVO) + rucaparib for chemotherapy (CT)-naïve metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Mini oral session - Genitourinary tumours, prostate
Resources:
Abstract
Slides
Webcast